Menopause and Perimenopause: Symptoms and Support

Menopause is a universal experience for half the population, yet it remained largely undiscussed in public until relatively recently. That silence left a great many women unprepared for symptoms they did not recognise.

The picture is improving. Awareness has risen sharply, workplaces have begun to respond, and access to treatment has broadened. Confusion still surrounds the basics, though, particularly the distinction between menopause and the years leading up to it.

Here is what actually happens, what symptoms to expect and what support is available.

Menopause is a single point in time.

Technically, menopause is the point at which a woman has not had a period for twelve consecutive months. Everything before that is perimenopause, and everything after is postmenopause.

In the United Kingdom the average age of menopause is around fifty one, though the normal range is wide. Menopause occurring before the age of forty five is described as early, and before forty as premature ovarian insufficiency.

Menopause can also be induced by surgery to remove the ovaries, or by certain cancer treatments, in which case symptoms can begin abruptly rather than gradually.

Perimenopause causes most of the symptoms.

This is the crucial point that catches people out. The transitional phase can begin several years before periods stop, sometimes in the early forties or occasionally earlier.

During perimenopause, hormone levels fluctuate rather than simply declining. That fluctuation is what produces the unpredictability many women describe: symptoms that come and go, months that feel normal followed by months that do not.

Periods often become irregular in this phase, changing in frequency, length and heaviness. Because periods continue, many women do not connect their symptoms to hormonal change at all.

The symptom list is longer than most expect.

Hot flushes and night sweats are the best known, and affect a large majority of women to some degree. They can range from mild warmth to drenching episodes that disrupt sleep repeatedly.

Sleep disturbance, fatigue, joint and muscle aches, headaches, palpitations and changes in skin and hair are all common. Vaginal dryness, discomfort during sex and increased urinary frequency or infections result from tissue changes and often persist without treatment.

Psychological symptoms deserve particular mention because they are so frequently misattributed. Low mood, anxiety, irritability, reduced concentration and problems with word-finding and short-term memory are widely reported.

Many women describe being offered antidepressants for what was, in fact, a hormonal picture. Guidance is clear that antidepressants should not be first-line treatment for low mood arising from menopause alone.

Diagnosis is usually clinical.

For women over forty five with typical symptoms, diagnosis is generally made on the basis of symptoms and menstrual pattern rather than a blood test.

Hormone levels fluctuate so much during perimenopause that a single test can be misleading, showing a normal result on a day when levels happen to be higher.

Blood tests are more useful in younger women, where early menopause or premature ovarian insufficiency is being considered, and in certain other circumstances.

HRT is the main treatment for symptoms.

Hormone replacement therapy replaces the oestrogen that declines at menopause, with progestogen also given to women who still have a womb in order to protect the lining.

It is available as tablets, patches, gels and sprays, and vaginal preparations treat local symptoms with minimal absorption elsewhere. Testosterone is sometimes prescribed in addition, generally for reduced sexual desire where HRT alone has not helped.

Understanding of risk has shifted substantially since early studies caused widespread alarm two decades ago. Current guidance takes a more nuanced view, considering age, time since menopause, the type and route of HRT and individual risk factors.

That balance is genuinely individual. It is a conversation to have with a clinician who can weigh personal and family history rather than something to decide from a headline.

Non-hormonal options exist too.

HRT is not suitable or wanted by everyone. Certain non-hormonal prescription medications can reduce hot flushes, and cognitive behavioural therapy has good evidence for managing flushes, sleep problems and low mood.

Practical measures help as well: layered clothing, keeping bedrooms cool, reducing alcohol and caffeine where they appear to trigger flushes, regular physical activity and weight-bearing exercise for bone health.

Vaginal moisturisers and lubricants are available without prescription and can be used alongside or instead of local oestrogen.

Bone and heart health matter long term.

Oestrogen has a protective effect on bone, and its decline accelerates bone loss, raising the risk of osteoporosis in later life.

Cardiovascular risk also rises after menopause. This makes the postmenopausal years a sensible point to review blood pressure, cholesterol, activity levels and smoking status.

Weight-bearing and resistance exercise, adequate calcium and vitamin D, and not smoking all support long-term bone and heart health.

Support is available at work and beyond.

Many employers, including large North East organisations, have introduced menopause policies covering flexible working, uniform adjustments, temperature control and time off for appointments.

Charities including the Menopause Charity and Women's Health Concern provide reliable information, and the NHS website sets out treatment options clearly.

Anyone whose symptoms are affecting daily life should ask for a dedicated appointment rather than raising it at the end of one about something else. It is a substantial conversation and deserves the time.

Share your thoughts.

Do you think workplaces in the North East are taking menopause seriously enough?